Valted Seq has introduced the Single Cell AI Discovery Engine (SCADE), an innovative AI-powered genomics tool designed to transform the interpretation of genetic data.
Using advanced machine learning algorithms, SCADE aims to significantly enhance the speed and accuracy of insights from genomic sequences
It facilitates faster biomarker and drug discovery, personalised medicine, and more effective treatments for cellular diseases.
Unlike generic AI models, which often struggle with complex genomics problems, Valted Seq is trained by specialised engines for various genomics tasks, applications, and tissue types.
The tool was trained using highly homogeneous in-house-generated single-cell big data.
Valted Seq CEO Bardia Nezami said: “Our goal is to enable scientists such as biologists and biochemists to perform genomics and bioinformatics without writing computer code.
“Analysing genomics data, let alone from single cells, is incredibly complex. However, with SCADE we are democratizing that process. It enables robust analysis and interpretation at a scale never before possible expediting the journey toward life-saving breakthroughs.
“We have made this possible by training our AI models on high-quality homogenous single cell big data generated in-house consisting of tens of millions of cells.”
SCADE features hierarchical multi-layer models, including data management, a bioinformatics core, a basic large language model, and a specialised genomics layer.
It also comprises a specialised single-cell layer and an application-dependent layer.
The layers provide custom-tailored AI tools for specific use cases such as neurology, oncology, microbial, or immune system applications.
SCADE generates high-quality big data for training and fine-tuning AI genomics and bioinformatics tools via robotics.
It uses advanced AI algorithms to analyse multiple large-scale datasets simultaneously, significantly reducing the time to identify variations and patterns.
The tool employs state-of-the-art models to minimise false positives and negatives, enhancing confidence in critical decisions.
In addition, it provides scientists with an intuitive interface for exploring and analysing genomic data, creating reports, and uncovering hidden relationships and reliable targets.
Its scalability allows it to handle both small-scale lab studies and large-scale projects, ensuring accessibility and flexibility for a wide range of users.
Building on its superior speed and accuracy, SCADE provides a significant advantage for organisations aiming to lead in precision medicine.
Bardia Nezami added: “Scientists need clear, actionable insights, and they need them quickly. AI-driven platforms like SCADE are no longer just ‘nice to have’; they are rapidly becoming the foundation upon which modern genomic science stands.
“Researchers worldwide are seeking innovative tools that can streamline the interpretation of complex genomics data at very large scale and help them keep pace with rapid advancements in precision medicine.”
